Stocks · News reference
Acumen Announces New Findings Presented At AAIC 2026; JCR Collaboration Shows Improved Brain Penetration Of Anti‑Aβo Antibodies Via Transferrin Receptor Delivery In Mouse And Primate Models
EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 11:35 AM
- Checked
- Jul 15, 2026, 11:35 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Acumen Pharmaceuticals Q2 EPS $(0.45) Misses $(0.34) Estimate
Read original at benzinga8-K filing — Acumen Pharmaceuticals, Inc. (ABOS)
Filed: 2026-08-12 AccNo: 0001628280-26-055940 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarAcumen Pharmaceuticals shares are trading lower. The company highlighted enhanced brain delivery program data and early Alzheimer’s disease insights at Alzheimer’s AAIC 2026.
Read original at benzinga